CN2732244Y - Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent - Google Patents
Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent Download PDFInfo
- Publication number
- CN2732244Y CN2732244Y CNU2004200662507U CN200420066250U CN2732244Y CN 2732244 Y CN2732244 Y CN 2732244Y CN U2004200662507 U CNU2004200662507 U CN U2004200662507U CN 200420066250 U CN200420066250 U CN 200420066250U CN 2732244 Y CN2732244 Y CN 2732244Y
- Authority
- CN
- China
- Prior art keywords
- bag
- enterococcus
- lactobacillus
- packing inside
- packaging bag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000194033 Enterococcus Species 0.000 title claims abstract description 25
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 25
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 25
- 239000002131 composite material Substances 0.000 title claims description 6
- 241000186000 Bifidobacterium Species 0.000 title abstract 3
- 241000193830 Bacillus <bacterium> Species 0.000 title 1
- 238000004806 packaging method and process Methods 0.000 claims abstract description 36
- 241000193755 Bacillus cereus Species 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 238000012856 packing Methods 0.000 claims description 52
- 239000000843 powder Substances 0.000 claims description 42
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 14
- 241000304886 Bacilli Species 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 10
- 239000004033 plastic Substances 0.000 claims description 7
- 229920003023 plastic Polymers 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract 2
- 238000005469 granulation Methods 0.000 abstract 2
- 230000000968 intestinal effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
Images
Landscapes
- Packages (AREA)
Abstract
The utility model relates to a live bifidobacterium, lactobacillus, enterococcus and bacillus cereus tetrad dispersible agent, in particular to a bifidus tetrad pharmaceutical granulation dispersible agent used for treating intestinal canal diseases belonging to the field of medicinal and pharmaceutical substances. The utility model is a live tetrad dispersible agent with bifidobacterium, lactobacillus, enterococcus and bacillus cereus. The dispersible agent is composed of a visceral pharmaceutical mixture and a carrier dispersible agent bag which is composed of an inner packaging bag and an outer packaging bag. The inner packaging bag is composed of at least an auxiliary bag. The outer packaging bag enwraps the inner packaging bag. A dispersible agent bag continuously sealed by a plurality of auxiliary bags of the utility model aiming at the bifidus tetrad pharmaceutical granulations used for treating intestinal canal diseases is invented according to different dosages. The form of the inner bag is a concatenation sphere or a concatenation pillow shape. The inner packaging bags are integrally enwrapped by the outer packaging bag. The carry over is convenient and the raw material is saved. The patient can tear the dispersible agent bag in which the dosage is matched with the state of illness and age according to different states of illness and ages simultaneously. To take medicine is convenient for the patient.
Description
The technology neck
This utility model belongs to the medical supplies field, relates in particular to a kind of bifidoquater drug particles powder for the treatment of intestinal tract disease.
Background technology:
In the prior art, the preparation of treatment intestinal tract disease generally adopts tablet.Yet this utility model is a kind of mycopowder of four kinds of strains such as bacillus bifidus and a kind of microbial ecological agent for the treatment of intestinal tract disease of adjuvant of containing.Owing to wherein contain active bacteria, the technical scheme of tablet can cause a large amount of strains inactivation in preparation process in the prior art, is very significant so adopt the dosage form structure of powder for the bifidoquater medicine for the treatment of intestinal tract disease.
Simultaneously, the packing method of powder adopts every bag of independent packaging in the prior art, the powder cumulative volume of the single or multiple courses of treatment greatly, not portable.In addition, different according to the state of an illness and age, the pill taker has nothing in common with each other on medication dose, however existing powder adopts unitizing, just is printed on " due to illness feelings or age cut down according to the circumstance " at different patients in packaging bag.The application has invented the powder bag that encapsulates continuously according to the many son bags of various dose at the bifidoquater drug particles for the treatment of intestinal tract disease, and the spherical or serial connection pillow type of serial connection that is shaped as of inner bag, bag outside the whole parcel outside inner bag, not only be easy to carry about with one but also save raw material, simultaneously according to the different state of an illness and age, the powder bag of the peelable dosage that conforms to it of patient is conveniently taken medicine.
Summary of the invention:
The purpose of this utility model provides a kind of bifidoquater drug powder for the treatment of intestinal tract disease.Invention is artificial to solve every bag of independent packaging of employing that prior art Chinese medicine powder exists, the powder cumulative volume of the single or multiple courses of treatment greatly, not portative technical problem, invented the technical program.
Concrete technical scheme is:
Bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, described powder is made up of the powder granule and the powder bag that contain bacillus bifidus, lactobacillus, enterococcus, four kinds of strains of bacillus cereus, described powder bag is made up of packing inside bag 1 and outer packaging bag, described packing inside bag 1 is made up of at least one height bag 2, and described outer packaging bag wraps up described packing inside bag 1.
In concrete application, each son bag 2 of described packing inside bag is the pillow type, and is provided with the gap 3 that can conveniently tear between per two son bags 2, and described powder granule is divided in each height bag 2.The length range of described pillow type packaging bag is the 30-100 millimeter, and altitude range is the 5-40 millimeter, and packing inside bag 1 single wall is thick to be 70-100 μ m.
In concrete application, each son bag 2 of described packing inside bag 1 is circle or spheroid shape, and is provided with the gap 3 that can conveniently tear between per two son bags 2, and described powder granule is divided in each height bag 2.The diameter of the circle of described packing inside bag 1 or spheroid shape bag 2 or the scope of semidiameter are the 40-80 millimeter, and packing inside bag 1 single wall is thick to be 70-100 μ m.
In concrete application, described outer packaging bag closely wraps up packing inside bag 1, and the volume of outer packaging bag is the 1-50 milliliter.Described packing inside bag 1 and outer packaging bag are made by aluminum-plastic composite membrane.
In the application of reality, the strain in the described packing inside bag 1 comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described powder grain diameter 2050-70 μ m.
Content in the described packing inside bag 1 also comprises: the mixture of adjuvants such as Icing Sugar, lactose, dextrin, starch, precipitated calcium carbonate, calcium phosphate, kaolin.
This utility model: the production technology of bifidoquater powder is simple, needn't consider in the production process with excipient such as binding agents; Instantaneous hyperpyrexia and high pressure when simultaneously not having the tablet molding in the bifidoquater powder production process have been avoided the massive losses (generally will lose the finished product viable count in the tabletting process 5～10 times) of the viable count in the production process, greatly reduce cost; In addition, for the activity that guarantees medicine and drug effect and patient conveniently take medicine, the technical program has adopted the architectural feature of serial connection ball-type and serial connection pillow type.
Description of drawings:
Fig. 1 is the sketch map of this utility model embodiment 1;
Fig. 2 is the sketch map of this utility model embodiment 2.
Below in conjunction with concrete embodiment accompanying drawing is specifically described.
Wherein, 1 is packing inside bag; 2 is the son bag; 3 is gap
The specific embodiment:
Embodiment 1: the powder of serial connection pillow type.Bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, described powder is made up of the powder granule and the powder bag that contain bacillus bifidus, lactobacillus, enterococcus, four kinds of strains of bacillus cereus, described powder bag is made up of packing inside bag 1 and outer packaging bag, described packing inside bag 1 is made up of at least two son bags 2, and described outer packaging bag wraps up described packing inside bag 1.
Each son bag 2 of described packing inside bag 1 is the pillow type, and is respectively arranged with two packing gap 3 in the left and right sides of each son bag 2, and described powder granule is divided in each height bag 2.
The length range of described pillow type packaging bag is the 30-100 millimeter, and altitude range is the 5-40 millimeter, and packing inside bag 1 single wall is thick to be 70-100 μ m.Described outer packaging bag closely wraps up packing inside bag 1, and the volume of outer packaging bag is the 1-50 milliliter.
Strain in the described packing inside bag 1 comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described powder grain diameter 2050-70 μ m.
Content in the described packing inside bag 1 also comprises: the mixture of adjuvants such as Icing Sugar, lactose, dextrin, starch, precipitated calcium carbonate, calcium phosphate, kaolin.
Described packing inside bag 1 and outer packaging bag by aluminum-plastic composite membrane make as: plastics, aluminizer: PET/PE/ aluminizes/PE; Or PET/ aluminum plated PET/PE; Or PE/ aluminizes/PE
Embodiment 2: serial connection ball-type powder.
Bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, described powder is made up of the powder granule and the powder bag that contain bacillus bifidus, lactobacillus, enterococcus, four kinds of strains of bacillus cereus, described powder bag is made up of packing inside bag 1 and outer packaging bag, described packing inside bag 1 is made up of at least two son bags 2, and described outer packaging bag wraps up described packing inside bag 1.
Each son bag 2 of described packing inside bag 1 is spherical, and is provided with a packing gap 3 in a side of each son bag 2, and the mixture of described powder is divided in each spherical son bag 2; 50 millimeters of the diameters of ball-type bag 2, packing inside bag 1 single wall is thick to be 80 μ m.Outer packaging bag closely wraps up packing inside bag 1, and the volume of outer packaging bag is 35 milliliters;
Described packing inside bag 1 and outer packaging bag by aluminum-plastic composite membrane make as: plastics, aluminizer: PET/PE/ aluminizes/PE; Or PET/ aluminum plated PET/PE; Or PE/ aluminizes/PE;
1 strain comprises in the described packing inside bag:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described powder grain diameter 2050-70 μ m.
Content in the described packing inside bag 1 also comprises: Icing Sugar, lactose, dextrin, starch, precipitated calcium carbonate, calcium phosphate, kaolinic mixture.
Claims (9)
1, bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, described powder is made up of the powder granule and the powder bag that contain bacillus bifidus, lactobacillus, enterococcus, four kinds of strains of bacillus cereus, it is characterized in that: described powder bag is made up of packing inside bag (1) and outer packaging bag, described packing inside bag is made up of at least one height bag (2), and described outer packaging bag wraps up described packing inside bag (1).
2, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, it is characterized in that: each son bag (2) of described packing inside bag (1) is the pillow type, and be provided with the gap (3) that can conveniently tear between per two son bags (2), described powder granule is divided in each height bag (2).
3, bacillus bifidus according to claim 2, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, it is characterized in that: the length range of described pillow type packaging bag is the 30-100 millimeter, altitude range is the 5-40 millimeter, and packing inside bag (1) single wall is thick to be 70-100 μ m.
4, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, it is characterized in that: each son bag (2) of described packing inside bag (1) is circle or spheroid shape, and be provided with the gap (3) that can conveniently tear between per two son bags (2), described powder granule is divided in each height bag (2).
5, bacillus bifidus according to claim 4, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, it is characterized in that: the circle of described packing inside bag (1) or the diameter of spheroid shape bag or the scope of semidiameter are the 40-80 millimeter, and packing inside bag (1) single wall is thick to be 70-100 μ m.
6, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four is characterized in that: described outer packaging bag closely wraps up packing inside bag (1), and the volume of outer packaging bag is the 1-50 milliliter.
7, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four is characterized in that: the strain in the described packing inside bag (1) comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described powder grain diameter is 2050-70 μ m.
8, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four is characterized in that: described packing inside bag (1) and outer packaging bag are made by aluminum-plastic composite membrane.
9, according to the described bacillus bifidus of one of claim 1,4-8, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Pulvis of Block of Four, it is characterized in that:
Described packing inside bag (1) is made up of at least two son bags (2), each son bag (2) of described packing inside bag (1) is spherical, and be provided with the gap (3) that can conveniently tear between per two son bags (2), described powder granule is divided in each spherical son bag (2); 50 millimeters of the diameters of ball-type bag (2), packing inside bag (1) single wall is thick to be 80 μ m; Outer packaging bag closely wraps up packing inside bag (1), and the volume of outer packaging bag is 35 milliliters;
Described packing inside bag (1) and outer packaging bag are made by aluminum-plastic composite membrane;
Strain in the described packing inside bag (1) comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described powder grain diameter 2050-70 μ m;
Content in the described packing inside bag (1) also comprises: Icing Sugar, lactose, dextrin, starch, precipitated calcium carbonate, calcium phosphate, kaolinic mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2004200662507U CN2732244Y (en) | 2004-06-25 | 2004-06-25 | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2004200662507U CN2732244Y (en) | 2004-06-25 | 2004-06-25 | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2732244Y true CN2732244Y (en) | 2005-10-12 |
Family
ID=35068091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2004200662507U Expired - Lifetime CN2732244Y (en) | 2004-06-25 | 2004-06-25 | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2732244Y (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN113925886A (en) * | 2021-09-28 | 2022-01-14 | 杭州远大生物制药有限公司 | New application of tetrad live bacteria composition |
-
2004
- 2004-06-25 CN CNU2004200662507U patent/CN2732244Y/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN113925886A (en) * | 2021-09-28 | 2022-01-14 | 杭州远大生物制药有限公司 | New application of tetrad live bacteria composition |
| CN113925886B (en) * | 2021-09-28 | 2024-02-02 | 杭州远大生物制药有限公司 | New application of tetrad viable bacteria composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1100546C (en) | Micro-encapsulated lactobacilli for medical applications | |
| US20210268051A1 (en) | Methods of using smectite compositions for treating clostridium difficile associated diseases and symptoms | |
| CN108611295B (en) | Bacteroides fragilis for relieving endotoxin infection and application thereof | |
| CN102106925B (en) | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator | |
| CN104415061A (en) | Edible composition as well as preparation method and application thereof | |
| CN1883536A (en) | Orally administered cervus and cucumis polypeptide composition and preparation method thereof | |
| CN2732244Y (en) | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent | |
| CN1309425C (en) | Treating canker sores with patches to speed healing and relieve pain | |
| CN1631371A (en) | Oral administered bitter free powder of macrolide antibiotic, its prescription and preparation process | |
| CN1253781A (en) | CoA oral preparation for reducing blood fat and its preparation method | |
| CN1372925A (en) | Medicine release-controlled microcapsule with dual-layer membrane and its preparing process | |
| CN2732243Y (en) | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule | |
| CN105534948B (en) | A kind of vagina active bacteria formulation and preparation method thereof being stored at room temperature | |
| CN114190558A (en) | Oral instant film containing probiotics and preparation method thereof | |
| CN1227028C (en) | Use of gene recombination human lysozyme against drug resistant bacteria in preparation of medicine | |
| CN1193790C (en) | Thymosin composition injection and its prepn | |
| CN101612154A (en) | Contain the compositions of pivampicillin and preparation method, purposes | |
| CN1730014A (en) | Novel drug administration route of semen armeniacae amarum injection, its preparation process and new indications | |
| CN1872055A (en) | Compound preparation of amoxicillin and ambroxol hydrochloride suitable to use for children, prescription and preparation method | |
| CN1537541A (en) | Applicaton of montmorillonite inpreparing medicine | |
| CN1843372A (en) | Pharmaceutical compositions separately constituted by ambroxol and two other antibacterials | |
| CN1176664C (en) | Medicine for treating bacillary dysentery and enteritis | |
| CN1391899A (en) | Aseptic freeze-dried prostaglandin injection and its preparing method and use | |
| CN100335127C (en) | Powder of human lysozyme, its production method and application | |
| CN100335038C (en) | Preparation process and application of inorganic salt nanometer particle containing biological active material and enveloped Chinese medicinal ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Assignor: Liu Wei Contract fulfillment period: 2008.8.25 to 2014.6.25 Contract record no.: 2008330001755 Denomination of utility model: Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent Granted publication date: 20051012 License type: Exclusive license Record date: 20081106 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Assignor: Liu Wei Contract fulfillment period: 2008.8.25 to 2014.6.25 Contract record no.: 2008330001755 Denomination of utility model: Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent Granted publication date: 20051012 License type: Exclusive license Record date: 20081106 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.8.25 TO 2014.6.25; CHANGE OF CONTRACT Name of requester: HANGZHOU LONGDA XINKE BIOPHARMACEUTICAL CO., LTD. Effective date: 20081106 |
|
| ASS | Succession or assignment of patent right |
Owner name: HANGZHOU LONGDA XINKE BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU WEI Effective date: 20090911 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090911 Address after: No. nine, 63 Ring Road, Jianggan science and Technology Park, Hangzhou, Zhejiang Province, China: 310019 Patentee after: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: Hangzhou City, Zhejiang Province, Moganshan Road community room 6-503, zip code: 310005 Patentee before: Liu Wei |
|
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20140625 Granted publication date: 20051012 |